| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/QAI.0000000000000365 |
| P698 | PubMed publication ID | 25473882 |
| P2093 | author name string | Peter Williams | |
| Elizabeth Gould | |||
| David Margolis | |||
| Susan L Ford | |||
| Yu Lou | |||
| Stephen Piscitelli | |||
| Herta Crauwels | |||
| William Spreen | |||
| Marita Stevens | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 487-492 | |
| P577 | publication date | 2014-12-01 | |
| P1433 | published in | Journal of Acquired Immune Deficiency Syndromes | Q6294722 |
| P1476 | title | Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults | |
| P478 | volume | 67 |
| Q38672579 | A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective |
| Q41432653 | Antiretroviral chemoprophylaxis: new successes and questions |
| Q59356819 | Antiviral Activity of Cabotegravir against HIV-2 |
| Q40429647 | Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. |
| Q40100018 | Cardiovascular risk and dyslipidemia among persons living with HIV: a review |
| Q26783160 | Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review |
| Q89905960 | Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel |
| Q47603651 | Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles |
| Q58616897 | Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension |
| Q47377243 | Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. |
| Q41015337 | Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam |
| Q64076241 | Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection |
| Q40121806 | Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects |
| Q92862376 | Emerging role of nanosuspensions in drug delivery systems |
| Q38518434 | Formulation and pharmacology of long-acting cabotegravir |
| Q92376512 | GSK3732394: a Multi-specific Inhibitor of HIV Entry |
| Q36789620 | Global challenges keynote address in memoriam to colleagues lost in the Malaysia airlines 17 crash |
| Q30375397 | Implementation challenges for long-acting antivirals as treatment. |
| Q38765921 | In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents |
| Q47909110 | Investigational HIV integrase inhibitors in phase I and phase II clinical trials |
| Q33780895 | Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women |
| Q39371494 | Long acting systemic HIV pre-exposure prophylaxis: an examination of the field |
| Q90180918 | Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase |
| Q92191459 | Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV |
| Q38518438 | Long-acting antiviral agents for HIV treatment |
| Q40105215 | Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial |
| Q36262152 | Long-acting slow effective release antiretroviral therapy |
| Q36290753 | Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase |
| Q38807176 | Past, Present, and Future Drug Delivery Systems for Antiretrovirals |
| Q50046992 | Pharmacokinetic and Chemical Synthesis Optimization of a Potent d-Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery. |
| Q57023675 | Pharmacokinetic testing of a first generation cabotegravir prodrug in rhesus macaques |
| Q58551570 | Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor |
| Q92232313 | Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults |
| Q36816564 | Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection |
| Q43241737 | PrEP Implementation Science: State-of-the-Art and Research Agenda |
| Q90637197 | Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling |
| Q28079025 | Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date |
| Q38570500 | Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection |
| Q38802093 | Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients |
| Q38376336 | Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial |
| Q64104268 | Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies |
| Q38750666 | Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy |
| Q41544436 | The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge |
| Q35875746 | Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access |
Search more.